Article

Immune Effective Score As A Predictor Of Response To Neoadjuvant Trastuzumab Therapy And A Prognostic Indicator For HER2-positive Breast Cancer

2021-03-18

Abstract excerpt

<title>Abstract</title> <p><bold>Background: </bold>HER2-positive breast cancer (BC) is a highly aggressive phenotype and accounts for 15–20% of all BC cases. The role of the host immune features in predictive response to anti-HER2 therapies and prognosis in BC is already suggested. We aimed to develop a predictive and prognostic model and examine its relevance to the clinical outcomes of patients with HER2-posit...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work: 24a9c82c-8f8e-532d-95f9-71af27f509ac
DOI: 10.21203/rs.3.rs-84422/v2

Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest

Immune Effective Score As A Predictor Of Response To Neoadjuvant Trastuzumab Therapy And A Prognostic Indicator For HER2-positive Breast CancerDOI 10.21203/rs.3.rs-84422/v2Read

Identification of A 10-Gene Signature To Predict Efficacy of Neoadjuvant Therapy in Patients With HER2 Positive Breast Cancer.Semantic proximity Read

Identification of immune-related biomarkers for predicting neoadjuvant chemotherapy sensitivity in HER2 negative breast cancer via bioinformatics analysisSemantic proximity Read

Identification of a 10-Gene Signature Model to Predict Efficacy of Neoadjuvant Therapy in Patients With HER2 Positive Breast Cancer.Semantic proximity Read

Immune cell infiltration-based signature for prognosis and immunogenomic analysis in breast cancer.Semantic proximity Read

Novel Immune Subtypes Identification of HER2 Positive Breast Cancer Based On Immunogenomic LandscapeSemantic proximity Read

Integrated immune-related gene signature predicts clinical outcome for patients with Luminal B breast cancerSemantic proximity Read

Antigen-Presenting B-Cell Signature Predicts Response and Survival in HER2-Positive Breast CancerSemantic proximity Read

Predictive Value of Immune Genomic Signatures from Breast Cancer Cohorts Containing Data for Both Response to Neoadjuvant Chemotherapy and Prognosis after SurgerySemantic proximity Read

A deep-learning model based on histological images predicts survival and pathological response to neoadjuvant chemotherapy and chemoimmunotherapy in breast cancerSemantic proximity Read

Peripheral blood gene expression signatures of systemic immunity predict tumor microenvironment biology and therapeutic response in breast cancerSemantic proximity Read

Integrated tumor genomic and immune microenvironment analysis identifies predictive biomarkers associated with the efficacy of neoadjuvant therapy for triple-negative breast cancerSemantic proximity Read

MIRS: an AI scoring system for predicting the prognosis and therapy of breast cancerSemantic proximity Read